Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medlive Technology Co., Ltd. ( (HK:2192) ) has shared an update.
Medlive Technology reported solid growth for the year ended 31 December 2025, with revenue rising 15.0% year-on-year to RMB642.2 million, driven mainly by a 16.0% increase in its core precision marketing and corporate solutions segment. Gross profit climbed 17.8% to RMB385.4 million, while profit attributable to owners rose 6.1% to RMB334.3 million and non-HKFRS adjusted net profit increased 5.7% to RMB342.1 million, indicating improved scale but more modest bottom-line expansion.
The medical knowledge solutions and intelligent patient management solutions businesses also recorded revenue gains, though at slower rates of 6.0% and 2.4%, respectively, underscoring the company’s continued reliance on precision marketing as its primary growth engine. Overall, the results suggest Medlive is consolidating its position in healthcare-related digital marketing and solutions, with rising revenues across all categories supporting stable profitability and signaling ongoing demand from pharmaceutical and healthcare clients.
The most recent analyst rating on (HK:2192) stock is a Buy with a HK$11.00 price target. To see the full list of analyst forecasts on Medlive Technology Co., Ltd. stock, see the HK:2192 Stock Forecast page.
More about Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd. is a Cayman Islands–incorporated company listed in Hong Kong that operates in digital healthcare services, with a focus on precision marketing and corporate solutions for pharmaceutical and medical clients. The company also offers medical knowledge solutions and intelligent patient management tools, targeting the broader healthcare ecosystem and life sciences industry participants in China.
Average Trading Volume: 4,351,344
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.87B
For an in-depth examination of 2192 stock, go to TipRanks’ Overview page.